$1.45
3.33% today
Nasdaq, Apr 03, 06:38 pm CET
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Galmed Pharmaceuticals Ltd. Stock price

$1.50
-0.44 22.68% 1M
-3.54 70.24% 6M
-1.69 52.98% YTD
-2.38 61.36% 1Y
-313.50 99.52% 3Y
-578.10 99.74% 5Y
-1,688.70 99.91% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.08 5.63%
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Key metrics

Market capitalization $2.49m
Enterprise Value $-14.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 3.07
P/B ratio (TTM) P/B ratio 0.12
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-6.79m
Free Cash Flow (TTM) Free Cash Flow $-4.81m
Cash position $17.26m
EPS (TTM) EPS $-12.04
Short interest 2.96%
Show more

Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Galmed Pharmaceuticals Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

Buy
100%

Financial data from Galmed Pharmaceuticals Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.09 0.09
125% 125%
-
-0.09 -0.09
125% 125%
-
- Selling and Administrative Expenses 3.58 3.58
8% 8%
-
- Research and Development Expense 3.03 3.03
21% 21%
-
-6.70 -6.70
14% 14%
-
- Depreciation and Amortization 0.09 0.09
125% 125%
-
EBIT (Operating Income) EBIT -6.79 -6.79
13% 13%
-
Net Profit -6.32 -6.32
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galmed Pharmaceuticals Ltd. Stock News

Neutral
PRNewsWire
about 21 hours ago
TEL AVIV, Israel , April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission...
Neutral
PRNewsWire
14 days ago
TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol.

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Allen Baharaff
Founded 2000
Website galmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today